Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2009 Financial Results on July 23, 2009

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2009 financial results on Thursday, July 23, 2009, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Thursday, July 23, 2009, 2:00 p.m. Pacific Time (PT) / 5:00 p.m. Eastern Time (ET)

Telephone (877) 941-8610 (domestic) or (480) 629-9818 (international); conference ID 4114066
Webcast available at www.seattlegenetics.com in the News and Investor Information section
REPLAY access

Telephone replay will be available beginning at approximately 4:00 p.m. PT on July 23, 2009 through 4:00 p.m. PT on July 27, 2009 by calling (800) 406-7325 (domestic) or (303) 590-3030 (international); conference ID 4114066
Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com in the News and Investor Information section
About Seattle Genetics

Seattle Genetics is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company’s lead product candidate, SGN-35, is in a pivotal trial under a special protocol assessment with the FDA. SGN-35 is empowered by Seattle Genetics’ proprietary antibody-drug conjugate (ADC) technology comprising highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. In addition, Seattle Genetics has three other product candidates in ongoing clinical trials: dacetuzumab (SGN-40), lintuzumab (SGN-33) and SGN-70. Dacetuzumab is being developed under a worldwide collaboration with Genentech (a wholly-owned member of the Roche Group). Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen, Progenics, Daiichi Sankyo, MedImmune, a subsidiary of AstraZeneca, and Millennium: The Takeda Oncology Company, as well as an ADC co-development agreement with Agensys, a subsidiary of Astellas Pharma. More information can be found at www.seattlegenetics.com.


Contacts
Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com
 

Posted: July 2009

View comments

Hide
(web1)